Mark Ashby

4.3k citations
45 papers · 3.1k · 2 hit papers · h-index 23

Impact in

  • Oncology top 2%
    • Cancer Treatment and Pharmacology
    • HER2/EGFR in Cancer Research
    • Colorectal Cancer Treatments and Studies
  • Hematology top 2%
    • Platelet Disorders and Treatments
    • Hematopoietic Stem Cell Transplantation

Papers in

    • Hematopoietic Stem Cell Transplantation 11
    • Platelet Disorders and Treatments 7
    • Blood groups and transfusion 4
    • Acute Myeloid Leukemia Research 3
    • Polyomavirus and related diseases 4
    • Colorectal Cancer Treatments and Studies 3

Mark Ashby

44 papers receiving 2.9k citations

Mark Ashby's Hit Papers

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy 2013 · 408 citations
4080+8+16Years since publication2505007501000

Peers

Mark Ashby
Comparison fields: 5 of 128
  • Oncology 1.1k
  • Hematology 407
  • Cardiology and Cardiovascular Medicine 739
  • Rheumatology 417
  • Genetics 259
Replace Elliot Chartash with:
Elliot Chartash United States
Valerie Miké United States
Lars Fischer Germany
David Wofsy United States
Dan T. Vogl United States
Marie José Kersten Netherlands
Harald Holte Norway
Suzanne E. Dahlberg United States
Ephraim P. Hochberg United States
Ann S. LaCasce United States
Mark Ashby relative to Elliot Chartash United States Elliot Chartash's profile →
Citations per field
00.5×8.0×
Elliot Chartash · 1×
Citations per year

Countries citing papers authored by Mark Ashby

Since Specialization
Citations

This map shows the geographic impact of Mark Ashby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Ashby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Ashby more than expected).

Fields of papers citing papers by Mark Ashby

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Ashby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Ashby. The network helps show where Mark Ashby may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Ashby, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Ashby Line = papers co-authored together Mark Ashby links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 45 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Hit paper breakdown →
20021190
2
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
Hit paper breakdown →
2013408
3 2009244
4 2003152
5 2000137
6 201095
7 200072
8 199560
9 202060
10 199659
11 199849
12 198945
13 199743
14 201243
15
Preparative regimens for marrow transplantation containing busulphan are associated with haemorrhagic cystitis and hepatic veno-occlusive disease but a short duration of leucopenia and little oro-pharyngeal mucositis.
198736
16 202035
17
Bladder irrigation does not prevent haemorrhagic cystitis in bone marrow transplant recipients.
199132
18 199730
19 199126
20
Thrombopoietin mobilizes CD34+ cell subsets into peripheral blood and expands multilineage progenitors in bone marrow of cancer patients with normal hematopoiesis.
199826

About Mark Ashby

Mark Ashby is a scholar working on Hematology, Oncology, Emergency Medical Services, Pulmonary and Respiratory Medicine and Public Health, Environmental and Occupational Health, having authored 45 papers that have together received 3.1k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (11 papers), Platelet Disorders and Treatments (7 papers), Polyomavirus and related diseases (4 papers), Blood groups and transfusion (4 papers), Central Venous Catheters and Hemodialysis (4 papers), Colorectal Cancer Treatments and Studies (3 papers), Acute Myeloid Leukemia Research (3 papers) and Acute Lymphoblastic Leukemia research (3 papers). The work is most often cited by research in Oncology (1.1k citations), Hematology (407 citations), Cardiology and Cardiovascular Medicine (739 citations), Rheumatology (417 citations) and Genetics (259 citations). Mark Ashby has collaborated with scholars based in United States, Australia and South Korea. Frequent co-authors include Maureen Murphy, Deborah Keefe, Mary Kathryn Pierri, Virginia Paton, Andrew D. Seidman, Steven Shak, Clifford A. Hudis, Stanford J. Stewart, Mark Kozloff and Fairooz F. Kabbinavar. Their work appears in journals such as Biology of Blood and Marrow Transplantation, Blood, Journal of Intellectual Disability Research, Journal of Allergy and Clinical Immunology and Journal of Vascular and Interventional Radiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact